Psychiatry Research

Aim: The Patient Safety Screener-3 (PSS-3) is a brief suicide-risk screening tool. Item 1 of this scale assesses depressive mood but is not included in the total score. We examined the association of item 1 with depressive symptom severity and characterized the suicide-related risk captured by PSS-3 total positivity. Methods: We conducted a nationwide cross-sectional survey among resident physicians in Japan. Associations between PSS-3 item 1 endorsement and Patient Health Questionnaire-9 (PHQ-9) scores were evaluated using the Wilcoxon rank-sum test. Diagnostic performance of item 1 was evaluated using PHQ-9 positivity ([&ge;]10) as reference standard. We also compared Short-form Scale for Suicide Ideation (SIS-6) scores according to PSS-3 total positivity and PHQ-9 item 9 positivity. Results: A total of 1,844 participants were included. PSS-3 item 1 was endorsed by 443 physicians (24.0%), and 47 (2.5%) met the criteria for PSS-3 total positivity. Item 1 showed 79.3% sensitivity and 79.5% specificity for PHQ-9 positivity. SIS-6 scores were higher in the PSS-3 total-positive group than in the total-negative group (median [IQR], 6 [5-9] vs 0 [0-1]; p<0.001). The SIS-6 showed a higher area under the receiver operating characteristic curve (AUC) and Youden index using PSS-3 total positivity (AUC, 0.961; optimal cutoff, 3) than PHQ-9 item 9 positivity (AUC, 0.907; optimal cutoff, 2). Discussion: PSS-3 may support brief, simultaneous screening for depressive symptoms and suicide-related risk. Compared with PHQ-9 item 9, PSS-3 may capture a more severe spectrum of suicide-related risk. PSS-3 may facilitate identification of individuals requiring further mental health assessment.

Introduction: In 2020, Oregon became the first US state to legalize state-regulated psilocybin services. This study aims to examine: 1) the clinical and demographic characteristics, 2) psilocybin use motivations, and 3) differences in preparedness among patients seeking care in a Oregon- based pilot consult service specializing in psilocybin risk reduction. Methods: This retrospective chart review abstracted sociodemographics, trauma history, and medical and psychiatric risks of patients (November 2023 - September 2025). The Psychedelic Preparedness Scale (PPS), a validated self-report questionnaire, measured preparedness. Two sample t-tests examined associations of PPS scores by insurance, consult motivations, and prior psychedelic use. Results: Patients (N=29) had a mean age of 47.14 years (SD=15.9), were majority female (55.2%); White (82.8%); and privately insured (62.1%). Patients mostly sought psilocybin to address only a psychiatric concern (75.9%); 27.6% anticipated naturalistic (non-state regulated) use. Most patients were deemed low risk for adverse events. Prevalence of prior challenging psychedelic experiences (CPE) was 17.2%; 58.6% reported lifetime psilocybin use. 86.2% endorsed >1 form of lifetime trauma. Of PPS completers (N=23, 79%), mean score was 91.3 (SD = 23.99). Scores did not significantly differ by insurance; consultation motivation; CPE; prior psilocybin or psychedelic use. Conclusion: Patients utilizing a novel consultation service demonstrate a high prevalence of trauma, prior psilocybin use, and baseline preparedness. While preliminary, this is among the first descriptions of patients seeking medical and psychiatric consultation when considering psilocybin and highlight the potential role of healthcare systems in providing evidence-based patient education and risk reduction as interest in psychedelics grows.

Purpose: Involuntary psychiatric hospitalization under court orders requires careful balancing of legal obligations and clinical needs. Identifying factors that influence the length of these hospital stays helps clarify the relationship between legal frameworks and psychiatric treatment. This study aims to describe the socio-demographic, clinical, and legal profiles of individuals hospitalized under court warrants and to identify factors independently associated with the duration of forensic hospitalization. Methods: A retrospective study was conducted on 119 patients discharged between 2018 and 2023. Data were collected from medical and legal records, including socio-demographic details, psychiatric diagnoses, offense types, hospital stay lengths, and legal proceedings. Results: Most patients were men (91.6%) diagnosed with schizophrenia or schizoaffective disorder (97.5%), with high rates of comorbid substance use disorder (79.0%) and unemployment (85.7%). The median hospital stay was 19.0 months, representing 40% of the maximum statutory sentence. Patients with low-severity offenses served a larger share of their maximum sentence (47%) than those with high-severity offenses (24%). Time to first discretionary leave was the strongest predictor of total stay duration in univariable analysis. Conclusion: The finding that patients with minor offenses have longer hospital stays than those with serious offenses confirms that clinical factors, rather than offense severity, primarily influence discharge decisions. These findings support moving toward personalized, clinically focused, and family-inclusive forensic discharge planning while maintaining public safety.

Background: COVID-19 has been associated with persistent neuropsychiatric symptoms after recovery, including sleep disturbance and depressive symptoms. Patients who required hospitalization may be particularly vulnerable to post-acute psychological complications. This study aimed to determine the prevalence of insomnia and its association with depression among patients who had recovered from COVID-19 after hospitalization. Methods: This analytical cross-sectional study was conducted in 2023 at Shahid Beheshti Hospital, Zanjan, Iran. A total of 70 patients who had been hospitalized with PCR-confirmed COVID-19 and had recovered for at least 6 months were included. Data were collected from medical records and telephone interviews. Insomnia severity was assessed using the Insomnia Severity Index. Descriptive statistics, univariable and multivariable linear regression were used to analyze factors associated with insomnia severity. Results: The mean ISI score was 8.06 + 6.57. Overall, 40.0% of participants had at least subthreshold insomnia, and 17.1% had moderate to severe clinical insomnia. 30.0% of participants had some degree of depressive symptoms. In univariable analysis, higher depression score and lower educational level were associated with greater insomnia severity. In the multivariable regression model, depressive symptom severity remained independently associated with insomnia severity; each one-point increase in BDI-II score was associated with a 0.50-point increase in ISI score (adjusted {beta} = 0.50; 95% CI: 0.34-0.66; p < 0.001). Conclusion: Insomnia and depressive symptoms were common among patients who had recovered from COVID-19 after hospitalization. Depressive symptom severity was independently associated with greater insomnia severity. Routine screening for sleep disturbance and depressive symptoms may be beneficial in post-COVID follow-up care, particularly among previously hospitalized patients.

Background Children of parents with schizophrenia (SZ) or bipolar disorder (BP) show elevated rates of mental disorders. Longitudinal studies comparing offspring at familial risk with the background population are lacking. Method This study is an eight-year follow-up of the Danish High Risk and Resilience study. We examined four-year prevalence from age 11 to age15 (n=416), cumulative incidence by age 15 (n=516), persistency of mental disorders from age 11to age 15 (n=396) and global functioning in 15-year-old adolescents with familial high risk of SZ (FHR-SZ) or BP (FHR-BP) compared to population-based controls (PBC). We assessed mental disorders and global functioning with the Kiddie Schedule for Affective Disorders and Schizophrenia - Present and Lifetime Version (K-SADS-PL) and the Childrens Global Assessment Scale (CGAS). Results Four-year prevalence of any mental disorder was higher in FHR-SZ (51.3%, OR=2.39, 95% CI 1.49-3.83) and FHR-BP (45.9%, OR=1.98, 95% CI 1.16-3.37) compared with PBC (30.5%). Cumulative incidence of mental disorders by age 15 was higher in FHR-SZ (67.2%, OR=3.19, 95% CI 2.11-4.82) and FHR-BP (64.4%, OR=2.82, 95% CI 1.75-4.54) than in PBC (39.1%). Adolescents with FHR-SZ showed the highest rate of persistent mental disorders (33.3%), followed by FHR-BP (24.5%), and PBC the lowest (12.9%). Global functioning at age 15 was lower in FHR-SZ than in both FHR-BP and PBC, and FHR-BP showed lower scores compared with PBC. Between-group differences in cumulative incidences of mental disorders and in global functioning scores remained stable across ages 7,11 and 15. Conclusion Adolescents at FHR-SZ or FHR-BP show elevated risks of a range of mental disorders, psychiatric comorbidity, and lower global functioning from childhood to mid-adolescence, not confined to the disorders for which they carry familial risk. This vulnerability underscores the need for early detection and support for FHR offspring and their families.

Background: In the age of TikTok, YouTube, and Netflix, video streaming (VS) is highly popular among adolescents. Yet, risky to addiction-like viewing patterns (i.e., problematic (P)VS) may adversely affect well-being. Prevalence estimates based on established criteria and etiological understanding of this phenomenon remain scarce. It is associated with de-pression, a major issue within the youth mental health crisis. However, causality remains unclear. This study investigated prevalence trends of adolescent PVS and its temporal rela-tionship with depression. Methods: Population-based data were drawn from four annual waves (2022-2025) of a rep-resentative online survey among 3,477 German adolescents (aged 10-17 years). Weighted annual PVS prevalence estimates were calculated based on standardized measures applying ICD-11 criteria of behavioural addictions distinguishing pathological from hazardous behav-ioural patterns. A cross-lagged panel analysis examined the reciprocal relationship between PVS and depression over four years. Results: Prevalence of pathological VS ranged between 2 to 4% across waves. Hazardous VS prevalence was 13-14% from 2022 to 2024, before increasing to 25% in 2025. Up to 81% of adolescents with pathological VS (21% with hazardous VS) showed clinically relevant symptoms of depression, versus 8-9% of non-affected adolescents. Depression significantly predicted PVS in two of three lags ({beta}W1-W2=0.233, {beta}W2-W3=0.155), but not vice versa. Conclusions: Prevalence rates and their divergent associations with depression support dis-tinguishing hazardous from pathological VS and underline the clinical relevance of PVS. Depression preceded PVS, pointing to the role of maladaptive coping. This has direct impli-cations for effective intervention measures. Future research should clarify the mechanisms underlying this relationship.

Background: Major depressive disorder is a severe, recurrent and disabling condition. Although diagnosis and clinical monitoring are based on medical interviews and validated rating scales, speech and discourse analysis may provide complementary digital biomarkers reflecting depressive severity and clinical evolution. However, current evidence remains limited by methodological heterogeneity, predominantly cross-sectional designs, limited longitudinal data and underrepresentation of non-English-speaking clinical populations. Objective: The aim of the VOICE-DEP study is to develop and formalize a standardized, reproducible and clinically grounded protocol for the multimodal analysis of voice and discourse during medical interviews as a tool to support the diagnosis of depressive disorder and to assess whether speech-derived biomarkers change over time in parallel with clinical severity measures. Methods: VOICE-DEP is an observational, prospective, longitudinal pilot study of patients with major depressive disorder with a healthy control group, conducted in a hospital-based clinical setting in Spain. The study will include 25 adult patients with moderate or severe unipolar depression, with or without psychotic symptoms, and 50 healthy controls without a personal history of psychiatric disorders. Patients will be assessed at five time points: baseline (V0) and four monthly follow-up visits at 30, 60, 90 and 120 days. Healthy controls will be assessed once at baseline. The planned dataset comprises 175 voice recordings: 125 from patients and 50 from controls. At each assessment, the Montgomery-Asberg Depression Rating Scale related part of the medical interview, lasting approximately 10-30 minutes and including an initial free-speech segment, will be recorded using a standardized audio protocol. Acoustic, paralinguistic and linguistic features will be extracted and analyzed in relation to clinician-rated severity measures and self-reported symptoms. Ethics: This protocol has been reviewed and approved by the local Research Ethics Committee, which complies with the international standards of GCP CPMP/ICH/135/95 (Comunidad Foral de Navarra Research Ethics Committee; reference code: 2026.110). Written informed consent will be obtained from all participants before any study procedure. Voice recordings and clinical data will be pseudonymized, stored securely and processed in accordance with applicable Spanish and European data protection regulations. Expected outcomes: This protocol is expected to generate a clinically grounded Spanish-language longitudinal speech corpus and a transparent analytical framework for evaluating voice- and discourse-derived biomarkers as complementary tools for depression assessment and monitoring

Introduction: Auditory verbal hallucinations (AVH) affect 60-80% of people with schizophrenia, yet existing assessment tools inadequately capture their phenomenological complexity. Aim: To determine whether individuals with schizophrenia spectrum disorders could accurately match auditory verbal hallucination loudness to an external audio track, and to explore participant perspectives on this approach. Methods: Eight participants with schizophrenia spectrum disorders and active AVHs rated loudness via a Likert scale and by adjusting a headphone audio track to match their experience. Structured interviews and thematic analysis captured participant viewpoints. Results: No significant correlation was found between audio tool and Likert scale scores. Seven of eight participants reported the audio tool provided greater precision in quantifying AVH loudness and better enabled them to convey their internal experience to others. Discussion: Audio-matching tools may offer meaningful advantages over traditional scales for quantifying AVH loudness, even where statistical convergence with existing measures is absent. Limitations: Small sample size; loudness alone cannot fully capture the qualitative experience of hearing voices. Implications: This tool shows promise for longitudinal tracking of AVH loudness. Recommendations: Further investigation of digital approaches to AVH assessment is warranted.

Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely prescribed for type 2 diabetes and obesity, yet their neuropsychiatric safety profile remains incompletely characterized. We aimed to systematically evaluate neuro-adverse event (AE) signals for six GLP-1RAs and to validate key findings using population-based data. Methods We conducted disproportionality analysis of FAERS data for semaglutide, liraglutide, dulaglutide, tirzepatide, exenatide, and lixisenatide. RORs were calculated for 93 predefined neuro-AE MedDRA PTs across 11 neurological categories. External validation used NHANES 2013-2018 (n=17,057; 70 GLP-1RA users) with survey-weighted regression. Results We identified 41 significant neuro-AE signals. Semaglutide showed the strongest neuromuscular signal, muscle atrophy (ROR 3.94; 95%CI 3.42-4.54), corroborated by tirzepatide (ROR 2.35; 95%CI 2.04-2.71). Exenatide generated the highest psychiatric signal: nervousness (ROR 4.03; 95%CI 3.70-4.40). NHANES confirmed higher depression odds (OR 2.05; 95%CI 1.32-3.19; P=0.001) and reduced sleep hours (beta -0.35; P=0.033). Conclusions GLP-1RAs carry multiple neuropsychiatric safety signals, including muscle atrophy as a potential class effect and depression risk corroborated by population-level data. These findings support heightened clinical monitoring.

Background: Generative AI is evolving at a rapid pace, and many individuals are utilizing chatbots for mental health support. The safety of chatbots amid suicide disclosures is a major public health focus. However, the rate and correlates of intentions to seek help from chatbots for suicide thoughts is unknown. Objective: We sought to understand intentions to seek help from chatbots for suicide thoughts, compared to informal, formal, and anonymous online sources. Methods: Participants with clinically significant depression or anxiety (N=58) completed the General Help Seeking Questionnaire regarding help-seeking intentions for suicide thoughts and general emotional problems. Two questions were added to assess intentions to seek help from chatbots and anonymous online sources. Wilcoxon tests were used to compare intentions to use chatbots with intentions to use anonymous online sources and with groupings of informal (e.g., friends, family) and formal (e.g., therapist, general practitioner) sources. Kendall's correlations were used to examine correlations among groupings and individual informal and formal sources, and regression models further examined individual source associations adjusting for general help-seeking intentions. Exploratory analyses assessed whether demographic characteristics, mental health symptoms, and suicide risk were associated with help-seeking intentions for chatbots. Results: Participants endorsed lower help-seeking intentions for suicide thoughts from chatbots than from informal and formal sources. Intention to use chatbots for suicide thoughts was not correlated with informal and formal sources but was correlated with anonymous online sources. At the individual source level, chatbot intentions were positively associated with intimate partners but negatively associated with outreach to friends after adjustment for general help seeking tendency. Anxiety symptom severity was positively correlated with chatbot use intentions, but not with other sources of support. Conclusions: While preliminary, intentions to use chatbots for suicide thoughts appear mostly disconnected from intentions to seek help from other informal and formal supports. Future studies should evaluate the dynamics of help seeking for suicide thoughts via chatbots amidst and, perhaps in place of, other sources of support.

Background: The October 7, 2023 attack in southern Israel was one of the deadliest terror attacks in modern history, with 1,182 fatalities, more than 4,000 wounded individuals, and 251 hostages. The Nova music festival, an all-night outdoor rave near the Gaza border, suffered the highest number of civilian casualties, with more than 370 festival attendees killed. Survivors were exposed to prolonged life-threatening trauma with similar characteristics and within a narrow time window. Many survivors also reported being under the acute influence of psychoactive substances during the attack and the following hours. This tragic combination of civilian mass trauma and naturalistic pharmacological exposure created a rare opportunity to study trauma processing prospectively. Objective: This paper describes the rationale, design, and methodology of the Nova Protocol, a multimodal longitudinal observational study of survivors of the October 7, 2023 Nova festival attack and a sociocultural comparison group. Methods: The protocol spans from the first weeks to approximately 24 months post-trauma and includes three major assessment time points. It integrates repeated online clinical assessments, prolonged wearable-sensor monitoring, ecological assessments, saliva-based endocrine and inflammatory markers, structural and functional MRI, cardiac interoception paradigms, online and in-scanner reinforcement-learning tasks, and semi-structured qualitative interviews. Primary outcomes are PTSD symptom severity (PCL-5) and general psychological distress (K6), supplemented by a rich battery of secondary measures. Conclusion: The Nova Protocol provides an unusually rich longitudinal framework for characterizing psychological, behavioral, physiological, inflammatory, neural, interoceptive, and subjective mechanisms that shape clinical trajectories after civilian mass trauma. Because psychoactive substance exposure was naturalistic and self-selected, findings will be interpreted as mechanistic and prognostic associations rather than causal effects. The protocol is expected to inform early risk detection and scalable post-disaster monitoring and intervention strategies, as well as unique insights into how psychoactive substances impact trauma processing.

Background: Major depressive disorder (MDD) is a severe mental illness associated with severe clinical consequences and substantial societal burden. It's characterized by immune-inflammatory dysregulation and immune sensitization. Objective: To determine whether in vitro ketamine attenuates phytohemagglutinin (PHA)/lipopolysaccharide (LPS)-induced immune sensitization in patients with MDD and healthy controls (HCs). Methods: Whole blood from 18 patients with MDD and 18 HCs was stimulated with PHA/LPS and exposed to ketamine (0.3 M, 0.6 M, and 6 M) for 72 hours. Cytokines, chemokines, growth factors, and composite immune profiles, including M1/M2 macrophages, T helper (Th)1/2/17, the immune-inflammatory response system (IRS), and compensatory immunoregulatory system (CIRS), were synthesized and determined. Results: Under PHA and LPS stimulation in vitro, the MDD group exhibited markedly elevated immune profiles, including M1, M2, Th1, Th2, Th17, IRS, CIRS, chemokines, and growth factors, consistent with immune sensitization. Significant group-by-treatment interactions were observed for Th1-Th2, M2, growth factors, IL-12(p70), M1, and chemokines. Ketamine produced minimal changes in HCs but broader suppression in MDD, particularly at the highest concentration, without normalizing the sensitized immune phenotype. Among the immune markers with no notable group-by-treatment interactions, ketamine exerted diagnosis-independent effects, decreasing MIP-1{beta}, IL-1&{beta}, Th1, TNF-{beta} IRS, IFN-{gamma}, and IL-2 compared to the control condition. Conclusions: Ketamine exhibited two distinct immunoregulatory patterns: selective, disease-dependent attenuation of sensitized immune pathways and broader, diagnosis-independent suppression of the stimulated immune response, predominantly at higher concentrations. However, these effects were insufficient to normalize the immune-sensitized phenotype of MDD.

Post-traumatic stress disorder (PTSD) is associated with high rates of comorbid personality disorders, which may contribute to PTSD severity. Among veterans with PTSD, obsessive compulsive personality disorder (OCPD) is common, with reported prevalence estimates ranging from 7-44%. Despite this, the relationship between OCPD traits and PTSD severity remains poorly understood. This retrospective, cross-sectional study examined associations between PTSD severity and OCPD traits in a naturalistic sample of 99 Veterans evaluated by a single clinician in a PTSD/Trauma Recovery Services clinic. PTSD symptoms were measured with the PTSD Checklist for DSM-V (PCL-5), and OCPD traits were measured with the Pathological Obsessive-Compulsive Personality Scale (POPS). Relationships between these two constructs were examined using Pearson correlations. Overall PTSD severity was significantly and positively correlated with total OCPD traits (r = 0.46, p < 0.001). Among OCPD domains, maladaptive perfectionism showed the strongest association with PTSD severity (r = 0.44, p <.001), followed by emotional overcontrol and reluctance to delegate (both r = .38, p < .01), rigidity (r = .35, p < .01), and difficulty with change (r = .28, p < .05). These findings suggest OCPD traits impact PTSD symptom burden in veterans, warranting further research and clinical attention.

Background: Adolescent suicide is a leading cause of death in Australia, arising from multiple determinants. Psychological distress, lifestyle behaviours and socioeconomic factors are associated with adolescent suicidality. Existing research has predominantly employed cross-sectional designs, limiting our understanding of how these factors interact over time. Longitudinal and data-driven approaches are needed to help identify the factors associated with the emergence of suicidality throughout adolescence. Method: Participants aged 12-17 years completed longitudinal measures of suicidal ideation, psychological distress, sleep quality, mindfulness, physical activity, eating habits, and social connectedness. Subgroups were determined via hierarchical cluster analysis, based on average scores across later timepoints (9-15). ANOVA and pairwise effect size calculations were used to compare clusters across variables, and their preceding developmental trajectories were examined using generalised additive mixed models (across earlier timepoints; 1-8). Clusters were also compared on self-reported wellbeing, long-term suicidality, and socioeconomic status. Result: Three clusters characterised by low-, moderate-, and high-severity of suicidal ideation and psychological distress, and poorer sleep, social connectedness, physical activity, mindfulness, and eating habits were identified. Across earlier timepoints, the high-severity group showed consistently elevated suicidality and deteriorating wellbeing and lifestyle scores. Conclusion: Youth with high levels of suicidality had greater psychological distress, lower wellbeing, lower socioeconomic status, and poorer lifestyle behaviours. This subgroup was also found to have poorer scores on wellbeing and lifestyle factors in their early adolescence. Findings highlight the importance of early, preventative interventions targeting both mental health and lifestyle factors to reduce suicidality in adolescents.

Background:Previous self-harm elevates the risk of repeat self-harm and suicide, but the prognostic value of events and clinician observations around the index event is unclear. We evaluated established and exploratory risk factors for suicide and repeat self-harm among patients presenting to emergency psychiatric units after a suicide attempt or nonsuicidal self-injury (NSSI). Methods: Multicentre cohort study in Sweden (n = 804). Outcomes were suicide and repeat self-harm at 1-year and 5-year follow-up, ascertained through linked national registers. Established risk factors included psychiatric diagnoses, prior suicidal behaviour, and sociodemographic characteristics; exploratory factors comprised past-week self-reported symptom changes and clinician observations. LASSO-regularised Cox regression models were fitted for established (n=21) and exploratory (n=11) risk factors. Results: During five-year follow-up, 285 (35%) individuals had a new episode of self-harm and 41 (5%) died by suicide. No risk factors reached statistical significance for suicide, although male sex was retained after regularisation (1-year hazard ratio [HR] = 3.57 [95% CI 0-8.33]; 5-year HR = 2.5 [0.03-4.55]). Three established risk factors were significantly associated with repeat self-harm: psychiatric inpatient care in the three months before the index event (1-year HR = 1.85 [1.3-2.6]; 5-year HR = 1.72 [1.23-2.65]), previous suicide attempt (1-year HR = 2.01 [0.79-2.4]; 5-year HR = 2.19 [1.27-2.6]), and borderline personality disorder (1-year HR = 1.82 [1.13-3]; 5-year HR = 1.67 [0.14-2.75]). Among exploratory risk factors, clinician-observed hopelessness (1-year HR = 1.72 [1.1-2.3]; 5-year HR = 1.51 [1.03-1.91]) and personality disorder features (1-year HR = 1.48 [0.96-2.05]; 5-year HR = 1.47 [1.04-1.95]) were associated with repeat self-harm. Conclusions: Risk factor profiles for repeat self-harm were consistent at 1 and 5 years. Beyond established risk factors, clinician-observed hopelessness and personality disorder features emerged as markers of risk, suggesting that qualitative clinician assessments may yield prognostic information not available from medical records alone.

Objective. To estimate lifetime and 12 month mental health contact gaps among Peruvian adults with survey-defined mental disorders, and to describe inequalities in contact, perceived need for care, and mental health service use. Methods. We analyzed the information for adults of the 2022 Peruvian National Mental Health Survey, a cross-sectional household survey. The primary outcome was the survey-weighted proportion of adults with a 12 month mental disorder who reported no contact with an included source of mental health-related care during that period; the lifetime contact gap was descriptive. Perceived need was assessed using two derived 12 month perceived-need measures based on direct ENSM variables and service contact routing items. Analyses incorporated weights, strata, and clusters. Adjusted prevalence ratios were estimated using survey weighted Poisson models. Results. The dataset contained information on 13,840 individuals; 13,833 had complete survey-design information. Contact gap denominators were 3,927 for lifetime disorders and 1,649 for 12-month disorders. The lifetime and 12-month contact gaps were 61.0% (95% CI 58.4-63.7) and 84.5% (95% CI 81.5-87.6), respectively. Rural estimates exceeded urban estimates in both periods; after adjustment, poverty and rural residence were associated with the lifetime gap, and extreme poverty with the 12-month gap. Among individuals meeting survey-based criteria for one or more 12-month mental disorders, 37.3% (95% CI 33.4-41.4) reported self-perceived need, whereas 25.6% (95% CI 21.8-29.8) reported that need had been identified by others. Annual psychological and psychiatric service use was 3.7% and 1.1%, respectively. Conclusions. Mental health contact gaps were high, particularly for one or more 12-month mental disorders, and were associated with social and territorial variables. These contact measures do not establish adequate, continuous, or effective treatment, which needs to be addressed to understand the impact of the Peruvian mental health reform.

Background: Personality change is a debilitating consequence of traumatic brain injury (TBI), yet its prevalence, characteristics, and treatment remain poorly understood. Methods: We completed a pre-registered (CRD42023440990) systematic review and meta-analysis searching four databases (MEDLINE, PsycINFO, EMBASE and CINAHL) for primary studies assessing personality change after TBI. We synthesised conceptualisation, prevalence, longitudinal outcome, lesion location and treatment. Prevalence was estimated using a random effect meta-analysis using the Paule-Mandel estimator, with subgroup, meta-regression and robustness analyses. Results: 101 studies were included in this review, seventeen of which were suitable for meta-analysis. Personality change was defined inconsistently although common symptoms involved the emergence or increase of affective, behavioural, and social disturbances, including irritability, depression, emotional instability, anger outbursts, social withdrawal, anxiety, impulsivity, restlessness, aberrant motor behaviours, and aggression. The prevalence of secondary personality disorder was estimated as 29.1% (CIs 22.5% - 36.2%) and prevalence of broad personality change was 68.1% (CIs 53.4% - 81.2%). Robustness analyses showed that the estimate for broad personality change should be treated with caution as it was unstable when adjusted for risk of bias and potential publication bias. Follow-up studies, although of varying quality, consistently showed personality change remained stable over long follow-up periods. The relationship between personality change and specific lesion locations in TBI remains unclear, likely due to the poor methodological quality of studies examining this association. Perhaps most concerning, there is limited evidence and very few systematic studies addressing treatment. Conclusion: Personality change is a common and persistent consequence of TBI. Varying definitions, and the lack of high-quality lesion mapping studies and systematic investigations into treatment highlights critical gaps in understanding and management.

Introduction People with severe mental illness (SMI) and learning disabilities (LD) experience significant health inequalities, with diet-related conditions contributing substantially to early and preventable death. Despite high levels of nutritional risk, the presence and effectiveness of nutritional screening in mental health (MH) and LD settings remains under-researched. This study aimed to investigate nutritional screening practices in UK inpatient MH and LD services from the perspectives of dietitians. Methods A cross-sectional mixed-methods study was conducted using a novel 22-question online survey. Data was collected via the British Dietetic Association Mental Health Specialist Group (April-June 2025). Quantitative data was analysed descriptively and qualitative data by reflexive thematic analysis. Findings were integrated and presented thematically. Ethical approval was granted by Teesside University (2025Mar26544). Results Forty-seven dietitians participated, most with substantial dietetic experience, from a range of MH settings. Screening practices were widely established and supported by policy and audit. However, participants reported low confidence in screening translating into meaningful patient care. Barriers to screening included appropriateness of available tools, time constraints, difficulty engaging distressed patients and poor prioritisation of physical health. Digital integration and wider infrastructure were also important. Dietitians rarely undertook screening directly, instead holding secondary or leadership roles, while screening was most often completed by nursing staff who were often perceived to place limited importance on the process. Existing tools, particularly the Malnutrition Universal Screening Tool (MUST), were viewed as insufficiently capturing the broader nutritional risks relevant to MH/LD populations, leading some services to adopt bespoke, unvalidated tools. Conclusion Concerns regarding the suitability of existing nutritional screening tools in MH/LD settings are consistent with previous literature. However, we suggest cautious use of unvalidated bespoke tools. Whilst there was no clear front runner, MH specific tools such as the St Andrews Nutrition Screening Instrument (SANSI) and the NutriMental Screener warrant further evaluation. Importantly, findings indicate that optimising tool choice alone is unlikely to improve screening effectiveness. Nutritional screening must be embedded within clear care pathways, supported by organisational leadership, digital infrastructure, and multiprofessional engagement to move beyond procedural completion and support meaningful clinical action to improve patient care.

Background: Emotion dysregulation is a core feature of bipolar disorder (BD), yet its behavioral expression during depressive episodes, and potential differences between its types, BD-I and BD-II, remain unclear. This study used automated facial-expression analysis during naturalistic affective film viewing to examine subtype-specific and context-dependent emotional responding in bipolar depression. Methods: The sample included 135 participants: 69 healthy controls and 66 patients with BD (BD-I, 23; BD-II, 43). Participants viewed nine emotionally evocative film clips spanning negative, positive, neutral, and socially threatening contexts, while their facial expressions were continuously recorded and quantified using computer vision-based facial-expression analysis. Results: Patients with BD-I showed a distinct, context-dependent facial-expression profile, characterized by greater negative responses across multiple contexts than other groups. Specifically, they showed increased sadness during sad, reward, and amusing clips, and elevated anger during sad and neutral clips. In socially threatening contexts, BD-I participants showed a multivalent pattern of elevated anger, fear, and joy, suggesting poorly coordinated or context-incongruent affective expression. In contrast, BD-II participants did not differ significantly from healthy controls on any emotion, despite depressive symptom severity comparable to BD-I participants. Conclusions: These findings suggest that facial-expression patterns in bipolar depression differ across subtypes. BD-I may be characterized by heightened negative reactivity and altered context-appropriate modulation of emotional expression, whereas BD-II may not show comparable alterations in overt facial output. Automated facial-expression analysis during naturalistic stimulation may provide a useful behavioral marker for characterizing subtype-specific affective disturbance in bipolar depression and related psychopathology.

Background: Personality traits are consistently associated with bipolar disorder (BD). However, their features across BD diagnostic subtypes and their modulation by demographic and health-related factors remain largely unexplored. This study aimed to characterize Big Five personality domains in individuals with BD compared to controls, and to examine differences between BD type I (BD-I) and BD type II (BD-II). Methods: We analyzed 833 participants from the MadManic cohort (300 BD subjects and 533 controls) with available Big Five Inventory-2 (BFI-2) data. Linear regression models were used to assess associations between personality traits and BD diagnosis, adjusting for relevant covariates. Additional comparisons were conducted across sex, age, and Body Mass Index (BMI), and between BD-I and BD-II patients. Results: BD was associated with higher Negative Emotionality (NE) and lower Extraversion and Conscientiousness. Conscientiousness was also inversely associated with BMI. Within the BD group, individuals with BD-I exhibited lower NE compared to those with BD-II. Stratified analyses indicated that elevated NE in BD was the most consistent domain across sex, age, and BMI subgroups, whereas differences in Extraversion and Conscientiousness varied depending on subgroup features. Conclusions: BD is characterized by a distinct personality profile marked by elevated NE and reduced Extraversion and Conscientiousness. NE emerged as the most robust domain associated with BD, which may also differentiate between subtypes, with higher levels observed in BD-II than BD-I. These findings highlight the relevance for considering demographic and health-related factors, particularly BMI, when interpreting personality patterns in BD, supporting the role of personality dimensions to examine clinical heterogeneity.